论文部分内容阅读
目的:研究分析氨溴索联合糜蛋白酶雾化吸入治疗小儿支气管肺炎的疗效效果,为小儿支气管肺炎的治疗提供相应的借鉴以及参考。方法:选取2010年4月-2013年8月期间我院收治867例支气管肺炎患儿,将全部患儿分为两组,对照组和治疗组,对照组患儿392例,治疗组患儿475例。对两组患儿进行相应药物性抗感染、止咳平喘等对症治疗,分析比较两组患儿的治疗效果。结果:治疗组轻症及重症患儿肺部体征缓解时间、症状缓解时间以及住院时间均明显短于对照组,两组比较差异存在统计学意义(P<0.05)。结论:氨溴索联合糜蛋白酶雾化吸入治疗小儿支气管肺炎有非常显著的治疗效果,氨溴索联合糜蛋白酶的使用可以将其作用最大程度的发挥出来,值得进一步推广使用。
Objective: To study the efficacy of ambroxol combined with chymotrypsin inhalation in the treatment of children with bronchopneumonia, and provide references for the treatment of bronchial pneumonia in children. Methods: A total of 867 children with bronchopneumonia were admitted to our hospital from April 2010 to August 2013. All children were divided into two groups: control group, treatment group and control group. 392 children in treatment group and 475 children in treatment group example. The two groups of children with the corresponding drug resistance, cough and asthma symptomatic treatment, analysis and treatment of children in both groups. Results: The pulmonary symptom relief time, symptom relief time and hospitalization time in the mild and severe children in the treatment group were significantly shorter than those in the control group. The difference between the two groups was statistically significant (P <0.05). Conclusion: Ambroxol combined with chymotrypsin inhalation for the treatment of bronchial pneumonia in children has a very significant therapeutic effect. The use of ambroxol combined with chymotrypsin can play its role to the maximum extent, which is worth further promotion and use.